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ABSTRACT: Purpose}Amifostine is a prodrug in which selectivity is largely determined by the
preferential formation and uptake of its cytoprotective metabolite, WR-1065, in normal tissues as a
result of differences in membrane-bound alkaline phosphatase activity. It was hypothesized that
amifostine may be a good candidate for regional drug delivery to the liver because of its large
hepatic extraction and total body clearance. Methods}Rat livers were implanted with Walker-256
tumors. The tumor-bearing rats received 15 min infusions of amifostine (200mg/kg) via the portal
vein or the femoral vein. WR-1065 concentrations in the blood, liver and tumor were measured at
various times. Results}The WR-1065 tumor portal dosing AUC1560 was 40% of systemic dosing,
and tumor concentrations following portal dosing were one-fifth of that following systemic dosing.
The portal dosing WR-1065 liver AUC1560 was 60% higher than the values for systemic dosing. The
liver/tumor concentration ratios of WR-1065 following portal dosing were up to 8-fold higher than
the ratio following systemic administration. Unfortunately, systemic exposure to WR-1065 was
greater following portal vs systemic amifostine. Conclusions}Amifostine may provide increased
liver protection and decreased tumor protection from radio- or chemotherapy when administered
by the portal vein. However, portal dosing also increases systemic exposure to WR-1065, which is
associated with hypotension. Copyright # 2004 John Wiley & Sons, Ltd.
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Introduction
The tolerance of the liver to radiation therapy or
chemotherapy is too low to permit effective
treatment of hepatic carcinoma [1]. Therefore,
investigating strategies that could potentially
increase the therapeutic index of chemotherapy
or radiotherapy in the liver is of major impor-
tance. Amifostine is a potent chemo- and radio-
protective agent that has been shown to protect
various tissues from the cytotoxic effects of
radiation and/or chemotherapy without com-
promising tumor cell kill [2–5]. Amifostine is a
phosphorylated prodrug that is selectively hy-
drolysed in healthy tissue to the active metabo-
lite, the free thiol, WR-1065 [6]. In turn, WR-1065
detoxifies the active species associated with
radiotherapy and chemotherapy by forming
covalent bonds with alkylating agents, scaven-
ging free radicals and other mechanisms [7,8].
Alkaline phosphatase is the enzyme that is
responsible for the hydrolysis of amifostine to
WR-1065 [9]. This enzyme is membrane-bound
and localized in the blood vessels of tissues/
organs. Amifostine exerts its selectivity towards
benign tissue due to the differences in alkaline
phosphatase distribution and pH between
normal and tumor tissue. Tumors are less
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vascularized than benign tissue and, therefore,
less alkaline phosphatase is available to activate
amifostine to WR-1065 in the tumor. Further-
more, tumor pH is lower than that of normal
tissue and alkaline phosphatase is less efficient in
hydrolysing amifostine in the low pH environ-
ment of tumor cells. Finally, low pH may
decrease the rate of amifostine uptake into
cells [8].
The dose-limiting adverse effect of amifostine
is transient hypotension, which is dose depen-
dent and is associated with direct relaxation of
vascular smooth muscle mediated by WR-1065
[10]. Amifostine has a very high clearance and
short half-life, and there is some evidence
suggesting that its pharmacokinetics is saturable
[11]. The main metabolic pathway of WR-1065
elimination involves the formation of symmetri-
cal and nonsymmetrical disulfides that might
serve as a depot for the subsequent release of
active metabolite [12].
Regional pharmacokinetic experiments in dogs
have demonstrated that the liver has a high rate
of amifostine activation (i.e. EH 0.9), a process
that was not saturated over a wide dose range
[13]. Since the selective protection of healthy
tissue by amifostine is dependent on the loca-
lized conversion of the parent drug to WR-1065,
this high conversion rate suggested that the liver
might also be protected by amifostine.
Regional drug delivery is an approach de-
signed to increase the therapeutic index of
chemotherapy. Compared with systemic delivery,
higher drug concentrations can be achieved at
the desired target site and/or lower concentra-
tions can be delivered to sites of systemic toxicity.
Collins [14] derived an equation that predicts
the potential advantage of regional drug delivery.
The potential advantage of amifostine regional
administration to the liver (Rd), calculated
using the Collins equation, is between 20 and
37, indicating that regional administration of
amifostine to the liver will produce a liver/
systemic concentration ratio that is 20–37 fold
higher than the ratio achieved following systemic
administration. Liver Rd values were estimated
using amifostine clearance and liver extraction
ratios values from regional pharmacokinetic
studies in the dog [13]. However, this estimation
is limited because amifostine is a prodrug and
WR-1065 concentrations would actually deter-
mine liver protection. Nevertheless, our hypoth-
esis is that regional administration of amifostine
to the liver would enhance WR-1065 selectivity to
that region, since amifostine is converted solely
to WR-1065, and local conversion and uptake
could occur in normal tissue. Regional drug
delivery has been proven to be a valuable
method to increase the therapeutic index of other
chemotherapeutic drugs [15–17]. Therefore, re-
gional administration could potentially increase
the amifostine therapeutic index and, in turn,
allow escalating doses of radiation and/or
chemotherapy to be delivered to the liver with-
out inducing toxicity or compromising tumor cell
kill.
Amifostine is administered in the clinic as a
15min infusion 30 min before the start of
chemotherapy or radiotherapy [18]. However,
the recommended regimen may be too limited.
For example, activation in different tissues and/
or different administration routes may affect the
optimal start time for chemotherapy or radio-
therapy following amifostine administration. To
date, little experimental data supporting the
clinically approved administration regimen are
available.
In the present study, our objective was to
evaluate the potential advantage of amifostine
regional administration to the liver. Thus, the
concentrations of the active metabolite, WR-1065,
were determined in the blood, liver and tumor of
a tumor-bearing rat model. Rats received a
200mg/kg dose of amifostine over an infusion
period of 15 min, a regimen which is similar to
that used clinically. To evaluate regional admin-
istration to the liver, rats received amifostine
either through the femoral vein (systemic dosing)
or through the portal vein (regional dosing).
In an attempt to further increase selectivity of
protection of the liver compared with the tumor,
systemic and portal venous infusions were
compared. This reflects the fact that the tumors
in the liver are vascularized primarily through
the hepatic artery, whereas the normal liver
receives most of its blood supply from the portal
system [19,20]. Thus, amifostine selectivity
in the liver might be further enhanced by
use of the portal vein for regional ad-
ministration.
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Methods
Animals
Male Sprague-Dawley rats weighing approxi-
mately 250–300 g were obtained from Harlan
Sprague Dawley, Inc. (Indianapolis, Indiana).
They were housed in cages in a temperature–
humidity controlled room with a 12 h light–dark
cycle and fed with 5001 Rodent Diet (PMI
Nutrition International, Inc. Brentwood, Mo).
All animal procedures and study protocols were
approved by the University of Michigan Com-
mittee on the Use and Care of Animals.
Tumor implantation
The animals were anesthetized using a 60mg/kg
intraperitoneal injection of pentobarbital. A mid-
line abdominal incision was made and the liver
was exposed. Walker 256 cells were grown in
suspension cultures with RPMI media supple-
mented with 10% fetal calf serum and prepared
for injection by suspension in Hanks media. The
left lateral lobe and the right median lobe were
both injected with tumor cells (0.1ml) and the
peritoneum and abdominal wall were closed.
Focal tumors were allowed to grow for 12–14
days. The average size of the tumors at the time
of amifostine administration was 1.2 0.3 cm by
1 0.4 cm (measured using a ruler). The average
weight of the tumors at the time of dosing was
440 299mg.
Amifostine administration
The animals were anesthetized using a 60mg/kg
intraperitoneal injection of pentobarbital and the
femoral vein or portal vein was cannulated, as
previously described [21]. A 1ml aliquot of warm
saline was injected over 60 s into the portal vein
and the surgical bed was examined for leakage.
A dilution of 200mg/kg amifostine (ALZA
Pharmaceuticals, Palo Alto, or CA/US
Bioscience, West Conchohocken, PA) in normal
saline was prepared 5 min prior to the start of the
infusion. The amifostine solution was adminis-
tered over 15 min using a syringe pump
(Harvard Apparatus, South Natick, MA) set at
83.5 ml/min.
Experimental protocol
Tumor-bearing rats were divided randomly into
two equal groups, each receiving amifostine
either through the portal vein (regional) or the
femoral vein (systemic). Tumor and liver tissue
were collected 15, 20, 30, 45 and 60min after
initiating the drug infusion. In order to reduce
animal-to-animal variability during blood sam-
pling, parallel experiments were conducted in a
different group of tumor-bearing rats in which
serial samples were obtained. In these studies, six
blood samples (0.4ml) were sequentially drawn
from the femoral vein before amifostine dosing
(time zero) and at 15, 20, 30, 45 and 60min after
initiating the drug infusion. Blood samples were
replaced with equal volumes of warm normal
saline. In the blood sampling experiments, four
animals were studied after each dosing route (i.e.
systemic and regional).
Assay for WR-1065
WR-1065 is a free thiol that can readily form
disulfide bonds with proteins. In this study the
concentrations of free WR-1065 were measured in
the blood and in various tissues as described
below.
Sample preparation. The method was adopted from
Shaw and coworkers [6,11] with minor modifica-
tions. Tumor and liver samples were dissected,
rapidly rinsed with ice-cold normal saline,
weighed and frozen rapidly by dipping them in a
liquid nitrogen bath for 30 s. The samples were
stored at 708C for subsequent analysis. On the
day of analysis, the samples were homogenized
(1:2.5, w/v) in an ice-cold buffer containing 1.0m
perchloric acid and 2.7mm EDTA, as described
previously [6,11]. The homogenate was then
centrifuged at 1000g for 10min (at 08C) and WR-
251833 was added as an internal standard. The
samples were kept on ice during the entire
procedure in order to minimize the hydrolysis of
amifostine to WR-1065.
Blood samples were placed in tubes, contain-
ing ice-cold 1.0m perchloric acid and 2.7mm
EDTA in a ratio of 1:1 (v/v), immediately after
sampling. The mixture was then vortexed vigor-
ously and centrifuged at 1000 g for 10min (at
08C). The supernatant was stored at 708C for
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subsequent analysis. On the day of analysis, the
samples were thawed, WR-251833 was added as
an internal standard, and a 20 ml aliquot was
injected into the HPLC. Likewise, all samples
were kept on ice during the entire procedure in
order to minimize the hydrolysis of amifostine to
WR-1065. Using the described method, the lower
limit of detection for WR-1065 was 1.0 mm. The
method was validated by measuring samples
that were spiked with known concentrations of
WR-1065 (1, 4, 10 and 50 mm) on four different
days. The interday variability (precision) of WR-
1065 was less than 8.4% and the accuracy (bias)
was less than 8.6%.
HPLC analysis. Analysis was performed on a
Kratos (Ramsey, New Jersey) Spectraflow 400
HPLC pump. WR-1065 and the internal standard
were detected using a BAS (West Lafayette,
Indiana) LC-4C amperometric detector equipped
with a thin film mercury–gold amalgam elec-
trode. The Hg/Au electrode working potential
was set at +0.15V with respect to the Ag/AgCl
reference electrode. The column, 100 3mm,
3 mm particle size, ODS BAS (West Lafayette,
Indiana), was operated at room temperature. The
WR-1065 chromatography protocol employed a
mobile phase containing 0.1m of monochloroace-
tic acid, 3mm sodium-octyl sulfate pH 3.0, and 30%
methanol running at 0.6ml/min. Peak identifica-
tion was confirmed by comparing retention times
in samples with authentic standards. Quantifica-
tion was based on the peak area ratio of the
compound and the internal standard.
Statistics
Data are reported as mean SD unless otherwise
indicated. A two-tailed Student’s t-test was used
to compare drug samples. A p value of 40.05
was statistically significant. Area under the curve
was determined noncompartmentally using Win-
Nonlin version 3.1 (Pharsight, Mountain View,
California).
Results
WR-1065 concentrations in the tumor, liver and
blood, after regional or systemic dosing of
amifostine, are shown in Figure 1. As observed
in Figure 1A, WR-1065 concentrations in the
tumors were lower after portal vein infusion
compared with the femoral vein infusion at the
15, 20 and 30min time points. These data suggest
that portal vein administration of amifostine
offers less tumor protection than femoral vein
administration. At the 20min time point, the
mean tumor concentrations of WR-1065 were 44.8
and 229 mm for regional and systemic dosing,
respectively. At the 15 and 30min time points, the
mean tumor concentrations of WR-1065 were 84.8
Figure 1. WR-1065 concentrations in the tumor (A), liver (B),
and blood (C) of tumor-bearing rats following a 15min
infusion of amifostine via the portal vein (p.v.) or femoral vein
(i.v.). Data represent the mean SE from 3–4 determinations.
*Significant difference (p40.05)
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and 53.7 mm, respectively, after portal vein dosing
while the mean tumor concentrations were much
higher (273 and 343 mm, respectively), following
femoral vein dosing. Thus, a favorable trend
exists for lower WR-1065 tumor concentrations
following portal vein compared with femoral
vein administration of amifostine.
The concentrations of WR-1065 in the liver are
shown in Figure 1B. As seen in this figure, WR-
1065 concentrations appeared higher in the liver
after portal vein dosing at the 30, 45 and 60min
time points. However, a statistically significant
difference occurred only at the 45min time point.
The data suggest that portal vein infusion of
amifostine offers only marginally better liver
protection compared with femoral vein adminis-
tration. In addition, it should be noted that the
liver tmax of WR-1065 occurred at 20min after
systemic dosing while the liver tmax of active
metabolite occurred at 45min after regional
dosing. The mean WR-1065 Cmax was 720
263 mm in liver after regional dosing while the
mean WR-1065 Cmax was 519 355 mm in liver
after systemic dosing of amifostine.
The blood concentrations of WR-1065 are
shown in Figure 1C. As displayed in this figure,
WR-1065 blood concentrations were higher fol-
lowing a portal vein infusion compared with a
femoral vein infusion of amifostine. The data
indicate that portal vein administration of ami-
fostine results in a significant increase in WR-
1065 systemic exposure and that of femoral vein
administration. The mean WR-1065 Cmax in blood
was 572 108 mm after regional dosing, while it
was only 65.9 18.6 mm after systemic dosing.
The blood tmax after regional infusion was
observed at 20min; in contrast, the blood tmax
after systemic infusion was observed immedi-
ately after cessation of amifostine infusion (at
15min). In addition, it should be noted that the
coefficient of variation (%CV) after femoral vein
administration was considerably lower than after
portal vein infusion (27.2% and 42.2%, respec-
tively).
Figure 2 shows the liver/tumor concentration
ratios of WR-1065 following femoral vein or
portal vein infusions of amifostine to tumor-
bearing rats. As observed, the liver/tumor con-
centration ratios after portal vein administration
were always greater than the ratios after femoral
vein infusion. The largest difference was
achieved at the 30min time point, when the
liver/tumor concentration ratio of WR-1065
reached a maximum of about 12 after regional
dosing while the ratio after systemic dosing was
only about 1.5. The data suggest that portal vein
administration of amifostine would offer in-
creased liver protection and reduced tumor
protection compared with femoral vein adminis-
tration of drug.
Figure 3 shows the route-dependent concen-
tration ratio of WR-1065 (p.v./i.v.) in the
tumor, liver and blood. As seen in this figure,
WR-1065 blood concentrations were as
much as 21 times higher after portal vein than
after femoral vein administration. Likewise,
the liver concentrations of WR-1065 were as
much as three times higher after portal vein
administration compared with femoral vein
administration. In contrast, tumor levels of
WR-1065 after portal administration were
one-fifth of the levels after femoral vein
administration. The data suggest that while
amifostine offers a beneficial reduction in
tumor protection, portal vein administration of
amifostine offers a marginal increase in liver
protection as well as a substantial increase in
systemic exposure to WR-1065.
The body weight, dose, blood Cmax, AUC1560
and dose-normalized AUC1560 of WR-1065 after
Figure 2. Liver/tumor concentration ratios of WR-1065 in
tumor-bearing rats after a 15 min infusion of amifostine via
the portal vein (p.v.) or femoral vein (i.v.). Bars represent the
ratio of mean data
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portal vein or femoral vein administration to
tumor-bearing rats are shown in Table 1. As
shown in this table, there were no significant
differences between rat weight and dose amount.
The Cmax of WR-1065 following systemic admin-
istration was 66 mm, a value that is about nine
times smaller than the Cmax following portal vein
administration (572 mm) (p=0.0001). The AUC1560
of WR-1065 after portal vein infusion was
19339 1580min mmol/l, a value more than 13
times that of WR-1065 after femoral vein admin-
istration (1420 497min mmol/l) (p50.0001).
Furthermore, the dose-normalized AUC1560 of
WR-1065 was 287 32 and 21.2 8.7min/l after
portal vein and femoral vein administrations,
respectively (p50.0001). These findings indicate
that portal vein infusions of amifostine result in
nonlinear behavior of WR-1065 in the blood.
The body weight, dose, liver or tumor Cmax,
AUC1560 and dose normalized AUC1560 of WR-
1065 after portal vein or femoral vein dosing to
tumor-bearing rats are shown in Table 2. As seen
in this table, the AUC1560 value of WR-1065 in
the liver was about 60% higher after regional
dosing compared with systemic drug adminis-
tration. In contrast, the AUC1560 value of WR-
1065 in tumor after regional dosing was about
40% of the AUC1560 value after systemic drug
administration. In addition, the dose normalized
Figure 3. Concentration ratios of WR-1065 (p.v./i.v.) in the
blood, liver and tumor of tumor-bearing rats after a 15min
infusion of amifostine via the portal vein (p.v.) or femoral vein
(i.v.). Bars represent the ratio of mean data
Table 1. WR-1065 values in the blood of tumor-bearing rats for Cmax, AUC1560 and dose normalized AUC1560 after a 15min
infusion of amifostine via the portal vein (p.v.) or femoral vein (i.v.)a
Parameter Unit p.v. i.v. pb
Body weight g 337 12 342 26 0.7408
Dose mmol 315 11 320 25 0.7408
Cmax mmol/l 572 109 65.9 18.6 0.0001
AUC1560 minmmol/l 19339 1580 1420 497 50.0001
AUC1560/dose min/l 288 32 21.2 8.7 50.0001
aData are mean SD (n=4).
bp values were determined by two-tailed t-test.
Table 2. WR-1065 values in the liver and tumor of tumor-bearing rats for Cmax, AUC1560 and dose normalized AUC1560 after a
15min infusion of amifostine via the portal vein (p.v.) or femoral vein (i.v.)a
Parameter Unit Liver Tumor
p.v. i.v. p.v. i.v.
Body weighta g 385 369 385 369
Dosea mmol 360 345 360 345
Cmax
b mmol/l 720 520 173 343
AUC1560
c minmmol/l 25474 16402 4239 10263
AUC1560/dose
c min/l 70.8 47.6 11.8 29.8
aMean of 18 rats for p.v. or i.v. treatment.
bMean of 3 rats, representing one time point.
cAUC calculated using 5 time points, with 3 rats per time point.
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AUC1560 values in liver were 70.8 and 47.6min/l
after portal vein and femoral vein infusions,
respectively. In the tumor, however, the dose-
normalized AUC1560 values were 11.8min/l
after portal vein infusion and 29.8min/l after
femoral vein infusion. These findings further
illustrate that WR-1065 tumor exposure was
reduced but that WR-1065 liver exposure was
increased following regional as opposed to
systemic infusion of drug.
Discussion
In the present study, our main finding was that
portal vein administration of amifostine in-
creased WR-1065 selectivity to the liver com-
pared with systemic administration. This is
indicated by the reduction of WR-1065 tumor
concentrations following regional dosing to as
much as one-fifth the concentrations achieved
following intravenous infusion. The maximum
decrease occurred at the 20 and 30min time
points. This finding was further supported by
AUC1560 values of WR-1065 in tumor after
regional dosing that were about 40% of the
tumor AUC1560 values after intravenous infu-
sion. Moreover, WR-1065 concentrations in the
liver increased after p.v. amifostine infusion
compared with intravenous infusion of the same
dose. WR-1065 concentrations in the liver after
p.v. amifostine were more than twice the con-
centrations after i.v. dosing at the 45 and 60min
time points. Similarly, the AUC1560 values of
WR-1065 in the liver after p.v. amifostine were
about 60% higher than the AUC1560 values after
i.v. administration. Finally, the liver/tumor con-
centration ratios of WR-1065 after p.v. amifostine
were larger than these ratios after i.v. infusion of
amifostine for all the time periods tested. In
particularly, at the 30min time point, the liver/
tumor ratio of WR-1065 after portal vein amifos-
tine reached a maximum value of about 12,
whereas the ratio after intravenous infusion was
only about 1.5. These findings demonstrate that,
in comparison with intravenous amifostine,
portal vein infusion of the drug increased liver
exposure and reduced tumor exposure to WR-
1065. Hence, liver protection from radio- and/or
chemotherapy might well increase, while tumor
protection might decrease.
These findings agree with our previous pre-
dictions that portal vein infusion of amifostine
may be advantageous over systemic delivery
because of its ability to increase liver selectivity.
Our predictions were based on the high total
body clearance of amifostine and high liver
extraction in dogs [13]. Additionally, differences
in the blood supply between healthy liver and
tumor tissue [19,20] may contribute toward the
selective targeting of benign tissue after p.v. drug
administration.
Unfortunately, p.v. infusions of amifostine
increased substantially the systemic exposure to
WR-1065, compared with i.v. infusion of the same
dose. In turn, this higher exposure to WR-1065
could result in hypotension that might limit the
clinical use of p.v. infusions of parent drug [10].
Our study indicated that the AUC1560 of WR-
1065 in blood following p.v. administration of
amifostine was 14 times higher than the
AUC1560 values after i.v. administration. This
apparent nonlinear behavior of WR-1065, follow-
ing regional amifostine infusion, could be the
result of saturation in one or more of the
metabolic pathways involved in the elimination
of WR-1065. Alternatively, a WR-1065 induced
reduction in blood flow may be responsible for
this nonlinear behavior. The concentration of a
drug presented to the liver after p.v. infusion was
at least four times greater than the concentration
presented to the liver after systemic administra-
tion of the same dose [22]. Thus, the higher
concentrations of amifostine (and presumably
WR-1065) presented to the liver might result
in the nonlinear pharmacokinetic behavior
observed in WR-1065 blood concentrations.
A similar nonlinearity in the pharmacokinetics
of WR-1065 following p.v. infusion of amifostine
was observed in monkeys [22]. In this study,
rhesus monkeys received a 10min infusion of
150mg/kg amifostine by p.v. or i.v. dosing. The
plasma AUC of WR-1065 following p.v. infusion
was about 60% greater than following i.v.
infusion. The considerably higher increase in
WR-1065 AUC seen in our study, compared with
the Mangold study (14-fold vs 1.6-fold, respec-
tively), could be attributed to differences in
species (rats versus monkeys), differences
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in dose (200mg/kg versus 150mg/kg) and
in disease state (tumor-bearing rat versus healthy
monkeys). The reason for choosing the 200mg/
kg dose in our study was that this dose is the
minimum amount shown to have a radioprotec-
tive effect in rats [23], with an irradiation dose
modification factor of approximately 2 in hepa-
tocytes. This dose was also used in other rat
experiments [24,25].
We conclude that because p.v. administration
of amifostine significantly reduced tumor
concentrations of the active metabolite,
WR-1065, tumor protection from radio- and/or
chemotherapy may also be significantly reduced.
Moreover, the modest increase in the liver
exposure to WR-1065 resulting from p.v. amifos-
tine infusion may provide some increased
protection of healthy liver tissue. One significant
drawback, however, is that p.v. infusions of
amifostine did substantially increase systemic
concentrations of WR-1065 and might, thereby,
increase the likelihood of hypotension.
The mechanism of an increased systemic
WR-1065 after p.v. infusion of amifostine is
unclear at present. However, it may be due
to saturability of WR-1065 disposition or, alter-
natively, a reduction in blood flow to
the eliminating organs. Additional dose ranging
experiments are warranted to evaluate the
nature of the apparent nonlinear pharmacoki-
netics of amifostine and WR-1065, particularly
after regional dosing. This is especially important
if additional clinical benefit is to be achieved
by using amifostine as a chemo- and radio-
protectant agent during the treatment of hepatic
cancer.
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